HomeCompareAMGN vs HRC

AMGN vs HRC: Dividend Comparison 2026

AMGN yields 2.77% · HRC yields 11.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HRC wins by $2.09M in total portfolio value
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
HRC
HRC
● Live price
11.38%
Share price
$155.96
Annual div
$17.74
5Y div CAGR
40.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.26M
Annual income
$1,423,429.65
Full HRC calculator →

Portfolio growth — AMGN vs HRC

📍 HRC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNHRC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + HRC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
HRC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
HRC
Annual income on $10K today (after 15% tax)
$966.88/yr
After 10yr DRIP, annual income (after tax)
$1,209,915.20/yr
At 15% tax rate, HRC beats the other by $1,150,632.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + HRC for your $10,000?

AMGN: 50%HRC: 50%
100% HRC50/50100% AMGN
Portfolio after 10yr
$1.21M
Annual income
$746,586.75/yr
Blended yield
61.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMGN right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
HRC
Analyst Ratings
7
Buy
12
Hold
1
Sell
Consensus: Hold
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
0
HRC buys
0
No recent congressional trades found for AMGN or HRC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNHRC
Forward yield2.77%11.38%
Annual dividend / share$9.66$17.74
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%40.3%
Portfolio after 10y$164.2K$2.26M
Annual income after 10y$69,743.86$1,423,429.65
Total dividends collected$133.8K$2.14M
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyHold

Year-by-year: AMGN vs HRC ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrHRC PortfolioHRC Income/yrGap
1← crossover$11,111$411.31$12,296$1,595.93$1.2KHRC
2$12,524$634.70$15,730$2,573.05$3.2KHRC
3$14,394$993.52$21,147$4,316.00$6.8KHRC
4$16,987$1,585.83$30,235$7,608.15$13.2KHRC
5$20,776$2,599.19$46,615$14,263.36$25.8KHRC
6$26,645$4,414.70$78,712$28,834.27$52.1KHRC
7$36,373$7,863.06$148,063$63,841.01$111.7KHRC
8$53,826$14,907.12$315,890$157,462.80$262.1KHRC
9$88,231$30,636.84$778,498$440,495.17$690.3KHRC
10$164,151$69,743.86$2,256,422$1,423,429.65$2.09MHRC

AMGN vs HRC: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

HRCStock

Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000 systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.

Full HRC Calculator →
📬

Get this AMGN vs HRC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.